RxDoctor Payments Data

Samson Sheih, MD

Family Medicine · Conroe, TXNPI 1700880424

Payments from drug & device makers

$13,279in general payments, 2019–2025

Across 753 payments — averaging $17.63 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$2K
  • AstraZeneca$1K
  • AbbVie$1K
  • Novo Nordisk$1K
  • Lilly USA, LLC$1K
  • Boehringer Ingelheim$1K
  • plus $5K from 37 others

What the payments were for

  • Food & beverage$13,19299%
  • Education$871%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,279 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$56,443
Medicare patients
194
Services billed
1,196

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide102$131,546
MounjaroTirzepatide91$125,948
JardianceEmpagliflozin101$103,419
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$60,655
FarxigaDapagliflozin Propanediol45$52,340
EliquisApixaban22$28,779
Synjardy XrEmpagliflozin/Metformin Hcl20$18,696
LinzessLinaclotide24$18,598
Repatha SureclickEvolocumab17$14,683
JanuviaSitagliptin Phosphate11$14,413
MyrbetriqMirabegron18$12,066
XareltoRivaroxaban11$11,612
TrulancePlecanatide12$6,842
Amlodipine-ValsartanAmlodipine Besylate/Valsartan34$5,005
BelsomraSuvorexant12$4,741

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$1,368$131,546102 claims
Lilly USA, LLCMounjaro$1,157$125,94891 claims
Boehringer IngelheimJardiance, Synjardy Xr$1,033$122,116121 claims
GSKTrelegy Ellipta$1,560$60,65539 claims
AstraZenecaFarxiga$1,481$52,34045 claims
PfizerEliquis$439$28,77922 claims
AbbVieLinzess, Synthroid$1,468$19,93348 claims
MerckJanuvia, Belsomra$173$19,15423 claims
Astellas Pharma US IncMyrbetriq$46$12,06618 claims
Johnson & JohnsonXarelto$275$11,61211 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCTrulance$646$6,84212 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Conroe

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →